For research use only. Not for therapeutic Use.
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research[1] [2] .
In whole blood, Enlimomab activates resting neutrophils in a complement-dependent manner[1] .
| Catalog Number | M093042 |
| CAS Number | 142864-19-5 |
| Purity | ≥95% |
| Reference | [1]. J Vuorte, et al. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol. 1999 Feb 15;162(4):2353-7. [2]. [2]Gregory J del Zoppo. Acute anti-inflammatory approaches to ischemic stroke. Ann N Y Acad Sci. 2010 Oct;1207:143-8. |
